CNBC Stock Blog
- Mulling Buffett's Stock Advice? Get in With REITs: Fund Managers
- So Now You Can’t Give Microsoft Away?
- Groupon Needs More Disclosure: Analyst
- China’s Steelmakers Set for Turnaround: Analyst
- Bulls Bet Silicon Motion Will Bounce
- Tobacco Stocks a Hot Dividend Play: Analyst
- Forget the Earnings, Disney’s Issue Is the Multiple: Analyst
- Drug Stocks Do Well in ‘Gloom and Doom’ Market: Analyst
ABOUT THE CNBC STOCK BLOG
RSS FEED
CNBC EXPLAINS
4-Star Biotech Stocks
Text Size 
Will Muggia likes biotech. Muggia's Touchstone Mid-Cap Growth Fund is up an average of 14.9 percent annually over the last three years -- and even this year, it's up 1.8 percent. So what are the 4-star portfolio manager's picks?
Recommendations:
Muggia likes Celgene [CELG
Loading...
()
], "one of the fastest-growing biotechnology companies in the world today. He expects the firm to have 40 percent earnings growth.
He praises Elan Pharmaceuticals [ELAN
Loading...
()
] for its auto-immune and Alzheimer's medicines. He says the latter illness has barely begun to be addressed medically, with plenty of potential left.
CNBC.com Web Exclusive:
(Not found on TV)
For CNBC.com readers, Muggia also recommends Chesapeake Energy [CHK
Loading...
()
].
Disclosures:
Muggia personally owns both Celgene and Elan, and the stocks are the largest holdings in his fund.
Data is a real-time snapshot *Data is delayed at least 15 minutes
